First human trial tests 'Rejuvenating' gene therapy for blinding eye diseases
NCT ID NCT07290244
Summary
This is the first study in people to test the safety of a new gene therapy called ER-100 for two conditions that damage the optic nerve and cause vision loss: open-angle glaucoma and NAION. Researchers will give a single dose to 18 adults and closely monitor them for side effects for up to 5 years. The goal is to see if the treatment is safe and well-tolerated before testing if it can help preserve or restore vision.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OPEN-ANGLE GLAUCOMA (OAG) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Charleston Neuroscience Institute
RECRUITINGCharleston, South Carolina, 29414, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Global Research Management, Inc.
RECRUITINGGlendale, California, 91204, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.